



Title	Characterization of the glycoproteins of bat-derived influenza viruses
Author(s)	Maruyama, Junki; Nao, Naganori; Miyamoto, Hiroko; Maeda, Ken; Ogawa, Hirohito; Yoshida, Reiko; Igarashi, Manabu; Takada, Ayato
Citation	Virology, 488, 43-50 <a href="https://doi.org/10.1016/j.virol.2015.11.002">https://doi.org/10.1016/j.virol.2015.11.002</a>
Issue Date	2016-01-15
Doc URL	<a href="http://hdl.handle.net/2115/64129">http://hdl.handle.net/2115/64129</a>
Rights	©2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International <a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Rights(URL)	<a href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</a>
Type	article (author version)
File Information	Maruyama.pdf



[Instructions for use](#)

1 **Characterization of the glycoproteins of bat-derived influenza viruses**

2

3 Junki Maruyama<sup>1</sup>, Naganori Nao<sup>1</sup>, Hiroko Miyamoto<sup>1</sup>, Ken Maeda<sup>2</sup>, Hirohito Ogawa<sup>3</sup>,  
4 Reiko Yoshida<sup>1</sup>, Manabu Igarashi<sup>1,4</sup>, and Ayato Takada<sup>1,4,5\*</sup>

5

6 <sup>1</sup>Division of Global Epidemiology, Research Center for Zoonosis Control, Hokkaido  
7 University, Sapporo, Japan

8 <sup>2</sup>Laboratory of Veterinary Microbiology, Joint Faculty of Veterinary Medicine, Yamaguchi  
9 University, Yamaguchi, Japan

10 <sup>3</sup>Hokudai Center for Zoonosis Control in Zambia, School of Veterinary Medicine, The  
11 University of Zambia, Lusaka, Zambia

12 <sup>4</sup>Global Station for Zoonosis Control, Global Institution for Collaborative Research and  
13 Education, Hokkaido University, Sapporo, Japan

14 <sup>5</sup>School of Veterinary Medicine, the University of Zambia, Lusaka, Zambia

15

16 \*Corresponding author: Research Center for Zoonosis Control, Hokkaido University,  
17 Sapporo 001-0020, Japan

18 Tel: +81-11-706-9502; Fax: +81-11-706-7310

19 E-mail: [atakada@czc.hokudai.ac.jp](mailto:atakada@czc.hokudai.ac.jp)

20

21 Key words: Bat influenza virus, hemagglutinin, pseudotyped vesicular stomatitis virus

22 Running head: Characterization of the bat influenza virus HAs

23 Abstract: 148 words

24 Text: 3057 words

25 **Abstract**

26 Recently found bat-derived influenza viruses (BatIVs) have hemagglutinin (HA) and  
27 neuraminidase (NA) gene segments distinct from those of previously known influenza A  
28 viruses. However, pathogenicities of these BatIVs remain unknown since infectious virus  
29 strains have not been isolated yet. To gain insight into the biological properties of BatIVs,  
30 we generated vesicular stomatitis viruses (VSVs) pseudotyped with the BatIV HA and NA.  
31 We found that VSVs pseudotyped with BatIV HAs and NAs efficiently infected particular  
32 bat cell lines but not those derived from primates, and that proteolytic cleavage with a  
33 trypsin-like protease was necessary for HA-mediated virus entry. Treatment of the  
34 susceptible bat cells with some enzymes and inhibitors revealed that BatIV HAs might  
35 recognize some cellular glycoproteins as receptors rather than the sialic acids used for the  
36 other known influenza viruses. These data provide fundamental information on the  
37 mechanisms underlying the cellular entry and host restriction of BatIVs.  
38

## 39 **Introduction**

40 Influenza A viruses (IAVs), which belong to the family *Orthomyxoviridae*, have 8  
41 segmented negative sense RNA genomes. IAV is one of the most important zoonotic  
42 pathogens, with high morbidity in humans, pigs, horses, and poultry. IAVs have two  
43 envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA), and are divided into  
44 subtypes based on antigenicity. IAVs of H1-16 HA and N1-9 NA subtypes have been  
45 isolated from water birds such as migratory ducks, the natural reservoir of IAVs (Fouchier  
46 et al., 2005; Kida and Yanagawa, 1979; Webster et al., 1992).

47 HAs are expressed as trimers on the virion surface (Wilson et al., 1981). HA is  
48 initially synthesized as an inactive precursor HA0 and subsequently cleaved into HA1 and  
49 HA2 subunits by trypsin-like proteases of host cells (Sakai et al., 2014). The proteolytic  
50 cleavage of the HA molecule is essential for IAVs to acquire infectivity (Lazarowitz et al.,  
51 1973; Wiley and Skehel, 1987). HA1 is responsible for virus binding to sialic acid  
52 receptors on the cell surface, and HA2 mediates membrane fusion under acidic conditions  
53 in endosomes, thereby delivering the viral genomic RNA into the cytoplasm of target cells  
54 (Matlin et al., 1981; Rust et al., 2004). NAs, expressed on the virion surface as tetramers,  
55 have sialidase activity that enables mature virus particles to be released from infected cells  
56 after budding (Colman, 1994; Webster et al., 1992).

57 Recently, IAV-like RNA genomes were detected in succession from 2 frugivorous  
58 bat species, little yellow-shouldered bats (*Sturnira lilium*) and flat-faced fruit bats (*Artibeus*  
59 *planirostris*) in Guatemala and Peru, respectively. The nucleotide sequences of the HA and  
60 NA of these bat-derived influenza viruses (BatIVs) were divergent from all previously

61 known IAVs and new subtypes, H17N10 and H18N11, have been proposed (Tong et al.,  
62 2012; Tong et al., 2013). However, infectious viruses have not been isolated yet. Previous  
63 studies by others tried to rescue BatIVs using a reverse genetics approach, but failed to  
64 generate infectious BatIVs (Juozapaitis et al., 2014; Zhou et al., 2014). Thus, the  
65 information on the biological properties of BatIVs is mostly speculative and the possible  
66 functions of BatIV HAs and NAs are only hypothetical, based on structural analyses (Li et  
67 al., 2012; Tong et al., 2013; Zhu et al., 2012; Zhu et al., 2013).

68 In this study, we utilized a vesicular stomatitis virus (VSV) pseudotype system,  
69 enabling us to directly analyze the biological functions of the BatIV glycoproteins, which  
70 presumably play important roles in the replication cycle and pathogenicity. We found some  
71 bat cell lines susceptible to VSVs pseudotyped with BatIV HAs and NAs. Our data suggest  
72 that BatIVs do not use sialic acids as a viral receptor and may have a limited host range, at  
73 least considering receptor engagement.

74

## 75 **Results**

76 **Generation of VSVs pseudotyped with BatIV HAs and/or NAs.** To investigate cellular  
77 entry mediated by BatIV glycoproteins, VSVs pseudotyped with BatIV HAs and/or NAs  
78 (VSV $\Delta$ G\*-H17N10, -H18N11, -H17, -H18, -N10, and -N11) were generated as described in  
79 Materials and Methods. We first observed the virions of these pseudotyped VSVs using  
80 transmission electron microscopy (Fig. 1). We found that the virions of all of these  
81 pseudotyped VSVs showed characteristic morphology (i.e. a bullet-like shape) similar to  
82 parental VSV $\Delta$ G\*-G. It was noted that VSVs pseudotyped with BatIV HA and NA (Fig.

83 1A and B), HA alone (Fig. 1D and E), and NA alone (Fig. 1G and H) all had numerous  
84 spikes on their surfaces, as was the case with VSVs pseudotyped with IAV HA (H3) and  
85 NA (N2) (Fig. 1C), H3 HA alone (Fig. 1F), and N2 NA alone (Fig. 1I). Immune electron  
86 microscopy with anti-H17 HA and anti-N10 NA antibodies revealed that both BatIV HA  
87 and NA were efficiently incorporated into VSV particles (Fig. 1K and L). No difference  
88 was found in the overall morphology among these VSV virions. These data indicated that  
89 BatIV HAs and NAs were efficiently incorporated into the VSV particles.

90

91 **Cell lines susceptible to VSVs pseudotyped with BatIV glycoproteins.** Since previous  
92 studies have suggested that cell lines commonly used for IAV propagation are  
93 nonpermissive for BatIVs, we screened various cell lines, including bat-derived cells, for  
94 susceptibility to pseudotyped VSVs (Table 1) (Fig. 2). VSVs pseudotyped with HAs and  
95 NAs of BatIVs and well-characterized IAV strains, A/WSN/1933 (H1N1) (WSN) and  
96 A/Aichi/2/1968 (H3N2) (Aichi), were generated and treated with trypsin before use, since  
97 BatIV HAs, like WSN and Aichi HAs, have a cleavage site potentially recognized by  
98 trypsin-like proteases (Tong et al., 2012; Tong et al., 2013). We found that VSV $\Delta$ G\*-WSN,  
99 -Aichi, and -VSV G infected all cell lines tested (Fig. 2A, B, and E). On the other hand,  
100 VSV $\Delta$ G\*-H17N10 and -H18N11 infected bat cell lines YubFKT1, IndFSPT1, and  
101 SuBK12-08, but not the other cell lines tested, except MDCK cells, which were much less  
102 susceptible than these bat cells. Since IndFSPT1 cells showed the highest susceptibility to  
103 VSV $\Delta$ G\*-H17N10 and -H18N11 (Fig. 2C and D), this cell line was used for the following  
104 experiments.

105

106 **Trypsin requirement for the HA function and the dispensability of NA in virus entry.**

107 IAV HAs are known to be cleaved into HA1 and HA2 subunits by trypsin-like proteases to  
108 acquire the ability to mediate membrane fusion (Klenk and Rott, 1988). Western blotting  
109 revealed that both H17 and H18 HAs were cleaved into HA1 and HA2 by trypsin treatment  
110 (Fig. 3A). Thus, we investigated the requirement of HA cleavage for infectivity of  
111 pseudotyped VSVs. As expected, VSVs pseudotyped with BatIV glycoproteins did not  
112 infect IndFSPT1 cells without trypsin treatment, in a manner consistent with other IAVs  
113 (data not shown), whereas trypsin-treated viruses efficiently infected this cell line (Fig. 2).  
114 These data indicated that the HA cleavage was a prerequisite for BatIV infectivity. Next, to  
115 clarify whether BatIV HAs was responsible for virus entry, VSV $\Delta$ G\*-H17N10, -H18N11,-  
116 H17, -H18, -N10, and -N11 were inoculated to IndFSPT1 cells and their infectivities were  
117 compared (Fig. 3B). We found that VSV $\Delta$ G\*-H17 and -H18 infected IndFSPT1 cells as  
118 efficiently as VSV $\Delta$ G\*-H17N10 and -H18N11, whereas the infectivity of VSV  
119 pseudotyped with WSN or Aichi HA alone was much lower than that of VSVs pseudotyped  
120 with both HA and NA of the respective viruses. VSV $\Delta$ G\*-N10 and -N11 showed no  
121 infectivity, similarly to VSVs pseudotyped with NAs of WSN and Aichi. These results  
122 suggest that BatIV HA is the only glycoprotein mediating both virus attachment and  
123 membrane fusion and that BatIV NA is dispensable during the entry into cells.

124

125 **Effects of chemical and enzymatic treatments of cells on susceptibility to VSVs**

126 **pseudotyped with BatIVs.** It is generally known that IAV HAs mediate membrane fusion



127 in a low pH-dependent manner (Kida et al., 1983; Rust et al., 2004). To investigate the  
128 requirement of endosomal acidification for BatIV HA-mediated membrane fusion,  
129 IndFSPT1 cells were treated with ammonium chloride, which is known to neutralize the pH  
130 of acidic intracellular compartments, and then infected with VSV $\Delta$ G\*-WSN, -Aichi, -  
131 H17N10, -H18N11, and VSV $\Delta$ G\*-G. Treatment of the cells with ammonium chloride  
132 markedly reduced the infectivity of VSV $\Delta$ G\*-H17N10 and -H18N11, as was the case with  
133 VSV $\Delta$ G\*-G, -WSN, and -Aichi, in a dose-dependent manner, suggesting that BatIV HAs  
134 require a low pH for membrane fusion, consistent with the other IAV HAs (Fig. 4A). To  
135 obtain information on the biological characteristics of cellular receptors for BatIVs,  
136 IndFSPT1 cells were pretreated with tunicamycin, pronase, or neuraminidase (i.e., an N-  
137 linked glycosylation inhibitor, mixture of proteases, and sialidase, respectively), and then  
138 infected with pseudotyped VSVs (Fig. 4B to D). Tunicamycin treatment markedly reduced  
139 the infectivities of VSV $\Delta$ G\*-G, -H17N10, and -H18N11, but less significantly those of  
140 VSV $\Delta$ G\*-WSN and -Aichi (Fig. 4B). Preincubation of cells with pronase reduced the  
141 infectivities of the pseudotyped VSVs, except for VSV $\Delta$ G\*-WSN (Fig. 4C).  
142 Neuraminidase treatment reduced VSV $\Delta$ G\*-WSN and -Aichi infectivities, but interestingly  
143 did not affect the infectivities of VSV $\Delta$ G\*-H17N10 and -H18N11 (Fig. 4D). We confirmed  
144 that no remarkable cytotoxicity was observed during these treatments (Fig. 4E). These  
145 results suggest that BatIV HAs do not recognize sialic acids which are critical components  
146 of the IAV receptor and some other molecules such as glycoproteins may serve as BatIV  
147 receptors.  
148

## 149 **Discussion**

150 In recent years, particular attention has been paid to bat-derived viruses since some  
151 species of bats have been reported to be reservoirs of several viral zoonotic pathogens (e.g.,  
152 lyssavirus, henipavirus, SARS coronavirus, and Marburgvirus) (Calisher et al., 2006; Smith  
153 and Wang, 2013; Wang et al., 2011; Wong et al., 2007). Although the zoonotic potential of  
154 BatIVs has not been fully evaluated yet, recent studies generated reassortant viruses that  
155 had HA and NA gene segments of well-characterized IAVs (i.e., H1, H3, and H7 HAs and  
156 N1, N2, and N7 NAs) and the other gene segments derived from BatIVs, and demonstrated  
157 that the reassortant viruses replicated in cultured cells and caused severe disease in mice  
158 (Juozapaitis et al., 2014; Zhou et al., 2014). However, characterization of BatIV HAs and  
159 NAs remains an open research problem, since reassortant viruses carrying the BatIV HA  
160 and NA gene segments have not been rescued due to the lack of information on cells  
161 susceptible to this novel virus. In this study, we first determined the potentially permissive  
162 bat cell lines using VSVs pseudotyped with BatIV HAs and NAs.

163 We demonstrated that VSV $\Delta$ G\*-H17N10 and -H18N11 efficiently infected the  
164 bat-derived cell lines IndFSPT1, YubFKT1, and SuBK12-08. While IndFSPT1 was derived  
165 from *Pteropus giganteus* (family *Pterodidae*), YubFKT1 and SuBK12-08 were prepared  
166 from bats belonging to the same species (*Miniopterus* sp., family *Miniopteridae*). Based on  
167 a phylogenetic study of bats (Agnarsson et al., 2011), *Miniopteridae* belongs to the same  
168 cluster as *Phyllostomidae*, from which H17N10 and H18N11 BatIVs were detected, little  
169 yellow-shouldered bats (*Sturnira lilium*) and flat-faced fruit bats (*Artibeus planirostris*),  
170 respectively (Tong et al., 2012; Tong et al., 2013). Thus, BatIV HAs appear to recognize

171 cell surface molecules shared among the bats at least in *Miniopteridae* and *Phyllostomidae*  
172 families. IndFSPT1 should also have such molecules since it showed the highest  
173 susceptibility to BatIV HA-pseudotyped VSVs. It was noted that VSV $\Delta$ G\*-H17N10 and -  
174 H18N11 also infected MDCK cells, although less efficiently than these bat cell lines. This  
175 result might contradict a previous report that H17 HA did not bind to the surface of MDCK  
176 cells (Sun et al., 2013). However, it is conceivable that the binding affinity of BatIV HA to  
177 MDCK cell surface molecules is quite low and thus below the level of detection in the  
178 assay used in the previous study. In the present study, MDCK cells indeed showed much  
179 lower susceptibility to BatIV HA-pseudotyped VSVs than YubFKT1, IndFSPT1, and  
180 SuBK12-08. Nonetheless, it would be interesting to clarify whether MDCK cells express  
181 some BatIV receptor molecules shared with the bat cell lines.

182 It is also noteworthy that VSV $\Delta$ G\*-H17N10 and -H18N11 did not infect Vero E6,  
183 HEK293, SK-L, and QT6 cells. Previous studies show that quails can act as an intermediate  
184 host in the interspecies spread of avian IAVs (Makarova et al., 2003; Perez et al., 2003;  
185 Uchida et al., 2011). Furthermore, pigs are thought to serve as “mixing vessels” for the  
186 production of reassortant viruses between avian and human IAVs (Chang et al., 2009;  
187 Hinshaw et al., 1981; Ito et al., 1998; Kida et al., 1994; Scholtissek et al., 1985). Our results  
188 suggest that BatIVs do not readily infect humans, pigs, or birds and support that notion that  
189 these viruses have limited zoonotic potential (Juozapaitis et al., 2014; Zhou et al., 2014).

190 It is known that VSV G protein and IAV HA recognize ubiquitous cell surface  
191 molecules for virus entry. VSV G recognizes various cell surface molecules and thus VSV  
192 exhibits remarkably robust and pantropic infectivity (Finkelshtein et al., 2013;

193 Johannsdottir et al., 2009; Lichty et al., 2004; Roche et al., 2008). IAV HAs recognize  
194 sialic acids typically occupying the terminal positions of glycoproteins or glycolipids  
195 (Gambaryan et al., 2005; Suzuki et al., 2000). Accordingly, VSV $\Delta$ G\*-G, -WSN, and -Aichi  
196 infected all cell lines used in this study, whereas we found that VSV $\Delta$ G\*-H17N10 and -  
197 H18N11 infected only particular bat cell lines and that neuraminidase treatment did not  
198 affect the infectivities of VSV $\Delta$ G\*-H17N10 and -H18N11. This result was in agreement  
199 with previous results based on the crystal structure analysis and surface plasmon resonance  
200 of sialylated glycans with  $\alpha$ 2,3-linkage or  $\alpha$ 2,6-linkage (Sun et al., 2013; Zhu et al., 2013).  
201 Glycan microarray analyses also showed that H17 HA did not display obvious avidity to  
202 any glycans (Sun et al., 2013). Interestingly, we found that the infectivities of VSV $\Delta$ G\*-  
203 H17N10 and -H18N11 were markedly reduced by the treatment of IndFSPT1 cells with  
204 tunicamycin, which inhibits N-linked glycosylation, leading to unfolding or misfolding of  
205 proteins and inhibition of glycoprotein expression. Pretreatment of the cells with pronase  
206 also reduced the infectivities of VSV $\Delta$ G\*-H17N10 and -H18N11. Taken together, our data  
207 suggest that some particular glycoprotein(s) serve as receptors for BatIVs.

208         Previous studies indicated that N10 NA did not have sialidase activity (Li et al.,  
209 2012; Zhu et al., 2012). It was also shown that most of the amino acid residues responsible  
210 for NA activity were substituted, and proposed that N10 NA protein should be termed an  
211 NA-like protein (Zhu et al., 2012). In this study, we found that VSVs pseudotyped with  
212 BatIV NAs alone were not infectious, confirming that NA did not play a central role in IAV  
213 entry into cells. However, it should be noted that the production efficiency of pseudotyped  
214 VSVs bearing WSN and Aichi HAs alone was much lower than that of VSVs pseudotyped

215 with both HAs and NAs, suggesting that NA activity facilitated virus release from infected  
216 cells and/or increased the HA function (Su et al., 2009). By contrast, no remarkable  
217 difference was found in the infectivity between VSVs pseudotyped with BatIV  
218 glycoproteins (i.e., HA alone vs. HA and NA). These data suggest that, unlike the other  
219 IAVs, the target molecules of BatIV HAs and NAs are different and that the “HA-NA  
220 balance” concept proposed for IAVs does not be applied to BatIVs.

221           Because H17N10 and H18N11 BatIVs have never been isolated, their ability to  
222 infect humans and other mammals and the pathogenic potential for these hosts can only be  
223 hypothesized. In this study, the replication-incompetent VSV pseudotype system enabled  
224 us to investigate the cellular tropism controlled by the interaction between BatIV HA and  
225 its cellular ligand, which might be some glycoproteins. Although a reverse genetics  
226 approach and *in vivo* experiments for the infectious BatIV are needed to provide direct  
227 evidence of its pathogenicity and host specificity, our data suggest that BatIV may  
228 preferentially infect particular bat species.

229

## 230 **Materials and Methods**

231 **Cells.** HEK293, HEK293T, and Vero E6 cells were grown in Dulbecco's modified Eagle's  
232 medium (DMEM) with 10% fetal calf serum (FCS) and penicillin-streptomycin. MDCK  
233 cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% calf serum,  
234 L-glutamine, and penicillin-streptomycin. Bat cell lines BKT1, FBKT1, YubFKT1,  
235 IndFSPT1, DemKT1, ZFBK11-97, SuBK12-08, and ZFBS13-76A were established as

236 described previously (Maeda et al., 2008; Maruyama et al., 2014). All bat cell lines were  
237 grown in RPMI-1640 medium with 10% FCS, L-glutamine, and penicillin-streptomycin.

238

239 **Construction of plasmids expressing HAs and NAs.** Coding regions of the HAs and NAs  
240 of BatIVs were synthesized in vector pUC19 or pUCFa, based on the nucleotide sequences  
241 of GenBank (accession numbers for H17 HA, N10 NA, H18 HA, and N11 NA: CY103892,  
242 CY103894, CY125945, and CY125947, respectively) (FASMAC). Each coding region of  
243 the viral proteins was amplified by PCR with primers including restriction sites, the kozak  
244 sequence, and the stop codon. After digestion by restriction enzymes, each gene was cloned  
245 into the mammalian expression vector pCAGGS (Niwa et al., 1991). H1 HA and N1 NA of  
246 A/WSN/1933 (H1N1) (WSN), and H3 HA and N2 NA of A/Aichi/2/1968 (H3N2) (Aichi)  
247 were cloned into pCAGGS as described previously (Muramatsu et al., 2013).

248

249 **Vesicular stomatitis viruses (VSVs) pseudotyped with HAs and/or NAs.** Using VSV  
250 containing the green fluorescent protein (GFP) gene instead of the receptor-binding VSV G  
251 protein gene (VSV $\Delta$ G\*-G), pseudotyped viruses with HAs and/or NAs of BatIVs, WSN,  
252 and Aichi were generated as described previously (Takada et al., 1997). VSVs pseudotyped  
253 with IAV glycoproteins were pretreated with trypsin (final concentration 0.0005%) for 30  
254 minutes at 37°C, followed by incubation with an anti-VSV G monoclonal antibody, VSV-  
255 G(N)1-9, to abolish the background infectivity of parental VSV $\Delta$ G\*-G (Nakayama et al.,  
256 2011). For virus titration, 10-fold diluted pseudotyped VSVs were inoculated into confluent  
257 monolayers of each cell line on 96-well plates, and the infectious unit (IU) in each cell line

258 was determined 20 hours later by counting the number of GFP-expressing cells under a  
259 fluorescent microscope.

260

261 **Electron microscopy.** Transmission electron microscopy was carried out as described  
262 previously (Maruyama et al., 2014). Pseudotyped VSVs fixed with 0.25% glutaraldehyde  
263 were adsorbed to collodion-carbon-coated copper grids and negatively stained with 2%  
264 phosphotungstic acid solution (pH=5.8). For immune transmission electron microscopy, we  
265 used an anti-HA2 monoclonal antibody (3N12-6-4) broadly cross-reactive to group 1 HA  
266 subtypes, anti-N10 NA mouse serum (FM0137) produced by immunization with a synthetic  
267 peptide corresponding to amino acid residues 328 to 343 (AQEKGGGGIQQGFILDE) of N10  
268 NA, and an immunogold-conjugated goat anti-mouse IgG (H+L) polyclonal antibody (BB  
269 International). Samples were examined with an H-7650 electron microscope (Hitachi) at  
270 80kV.

271

272 **SDS-PAGE and western blotting.** Pseudotyped VSVs were treated with or without  
273 trypsin (final concentration 0.0005%) for 30 minutes at 37°C and then mixed with SDS-  
274 PAGE sample buffer with 5% 2-mercaptoethanol and boiled for 5 minutes. After  
275 electrophoresis on 5–20% SuperSep (Wako), separated proteins were blotted on a  
276 polyvinylidene difluoride membrane (Millipore). The membrane was incubated with an  
277 anti-H3N2 chicken polyclonal antiserum or anti-HA2 monoclonal antibody 3N12-6-4,  
278 which reacts to H1, H2, H5, H6, H17, and H18 HAs, followed by incubation with  
279 peroxidase-conjugated rabbit anti-chicken IgY (H+L) or goat anti-mouse IgG (H+L)

280 (Jackson ImmunoResearch). The bound antibodies were visualized with Immobilon  
281 Western (Millipore).  
282  
283 **Cell treatment with enzymes and inhibitors.** IndFSPT1 cells were preincubated with the  
284 medium containing an endosomal acidification inhibitor, ammonium chloride (Wako), at  
285 37°C for 2 hours in a CO<sub>2</sub> incubator, and then infected with pseudotyped VSVs  
286 appropriately diluted to yield 200–1000 IUs, followed by incubation in the presence of  
287 ammonium chloride. IndFSPT1 cells were also pretreated with pronase (a mixture of endo-  
288 and exoproteases from *Streptomyces griseus*) (Calbiochem) (Narahashi et al., 1968), for 20  
289 minutes, an N-glycosylation inhibitor (tunicamycin from *Streptomyces* sp.) (Sigma) for 8  
290 hours, which blocks the reaction of UDP-GlcNAc and dolichol phosphate in the first step of  
291 glycoprotein synthesis, thus inhibiting the synthesis of N-linked glycoproteins, or  
292 neuraminidase from *Vibrio cholerae* (Roche) (Uchida et al., 1977) for 1 hour at 37°C in a  
293 CO<sub>2</sub> incubator. Treated cells were washed with serum free RPMI-1640 medium 3 times,  
294 and then incubated with pseudotyped VSVs appropriately diluted to yield 200–1000 IUs for  
295 1 hour. After adsorption of the virus, the inoculum was aspirated and the growth medium  
296 (10% FCS RPMI-1640 medium) was added. Cells were incubated for 20 hours, and  
297 infected cells were counted under a fluorescent microscope. Cell viabilities were assessed  
298 by the alamar blue assay. After treatments of each enzyme and inhibitor, cells were  
299 incubated with FCS-free RPMI-1640 medium containing 10% Alamar blue (Biosource) for  
300 2 hours, and fluorescence with excitation wavelength at 530-560 nm was measured using  
301 EnVision (PerkinElmer).



302

303 **Acknowledgments**

304 This work was supported by KAKENHI (15H01249), a Grant-in-Aid for Scientific  
305 Research from the Ministry of Education, Culture, Sports, Science and Technology  
306 (MEXT) and the Japan Society for the Promotion of Science (JSPS) (14J00026), Japan, and  
307 partly by the Japan Initiative for Global Research Network on Infectious Diseases (J-GRID)  
308 (15FM0108008H0001) and the Japan Science and Technology Agency (JST) and Japan  
309 International Cooperation Agency (JICA) within the framework of the Science and  
310 Technology Research Partnership for Sustainable Development (SATREPS)  
311 (15JM0110005H0004). Funding was also provided by the Program for Leading Graduate  
312 Schools from MEXT, Japan.

313

314 **References**

- 315 Agnarsson, I., Zambrana-Torrel, C.M., Flores-Saldana, N.P., May-Collado, L.J., 2011. A  
316 time-calibrated species-level phylogeny of bats (Chiroptera, Mammalia). *PLoS Curr.* 3,  
317 RRN1212.
- 318 Calisher, C.H., Childs, J.E., Field, H.E., Holmes, K.V., Schountz, T., 2006. Bats: important  
319 reservoir hosts of emerging viruses. *Clin. Microbiol. Rev.* 19, 531-545.
- 320 Chang, L.Y., Shih, S.R., Shao, P.L., Huang, D.T., Huang, L.M., 2009. Novel swine-origin  
321 influenza virus A (H1N1): the first pandemic of the 21st century. *J. Formos. Med. Assoc.*  
322 108, 526-532.
- 323 Colman, P.M., 1994. Influenza virus neuraminidase: structure, antibodies, and inhibitors.  
324 *Protein Sci.* 3, 1687-1696.
- 325 Finkelshtein, D., Werman, A., Novick, D., Barak, S., Rubinstein, M., 2013. LDL receptor  
326 and its family members serve as the cellular receptors for vesicular stomatitis virus. *Proc.*  
327 *Natl. Acad. Sci. U. S. A.* 110, 7306-7311.
- 328 Fouchier, R.A., Munster, V., Wallensten, A., Bestebroer, T.M., Herfst, S., Smith, D.,  
329 Rimmelzwaan, G.F., Olsen, B., Osterhaus, A.D., 2005. Characterization of a novel  
330 influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. *J. Virol.*  
331 79, 2814-2822.
- 332 Gambaryan, A., Yamnikova, S., Lvov, D., Tuzikov, A., Chinarev, A., Pazynina, G.,  
333 Webster, R., Matrosovich, M., Bovin, N., 2005. Receptor specificity of influenza viruses  
334 from birds and mammals: new data on involvement of the inner fragments of the  
335 carbohydrate chain. *Virology* 334, 276-283.

336 Hinshaw, V.S., Webster, R.G., Easterday, B.C., Bean, W.J., Jr., 1981. Replication of avian  
337 influenza A viruses in mammals. *Infect. Immun.* 34, 354-361.

338 Ito, T., Couceiro, J.N., Kelm, S., Baum, L.G., Krauss, S., Castrucci, M.R., Donatelli, I.,  
339 Kida, H., Paulson, J.C., Webster, R.G., Kawaoka, Y., 1998. Molecular basis for the  
340 generation in pigs of influenza A viruses with pandemic potential. *J. Virol.* 72, 7367-7373.

341 Johannsdottir, H.K., Mancini, R., Kartenbeck, J., Amato, L., Helenius, A., 2009. Host cell  
342 factors and functions involved in vesicular stomatitis virus entry. *J. Virol.* 83, 440-453.

343 Juozapaitis, M., Aguiar Moreira, E., Mena, I., Giese, S., Riegger, D., Pohlmann, A., Hoper,  
344 D., Zimmer, G., Beer, M., Garcia-Sastre, A., Schwemmle, M., 2014. An infectious bat-  
345 derived chimeric influenza virus harbouring the entry machinery of an influenza A virus.  
346 *Nat. Commun.* 5, 4448.

347 Kida, H., Ito, T., Yasuda, J., Shimizu, Y., Itakura, C., Shortridge, K.F., Kawaoka, Y.,  
348 Webster, R.G., 1994. Potential for transmission of avian influenza viruses to pigs. *J. Gen.*  
349 *Virol.* 75 ( Pt 9), 2183-2188.

350 Kida, H., Webster, R.G., Yanagawa, R., 1983. Inhibition of virus-induced hemolysis with  
351 monoclonal antibodies to different antigenic areas on the hemagglutinin molecule of  
352 A/seal/Massachusetts/1/80 (H7N7) influenza virus. *Arch. Virol.* 76, 91-99.

353 Kida, H., Yanagawa, R., 1979. Isolation and characterization of influenza A viruses from  
354 wild free-flying ducks in Hokkaido, Japan. *Zentralbl Bakteriol Orig A* 244, 135-143.

355 Klenk, H.D., Rott, R., 1988. The molecular biology of influenza virus pathogenicity. *Adv.*  
356 *Virus Res.* 34, 247-281.

357 Lazarowitz, S.G., Compans, R.W., Choppin, P.W., 1973. Proteolytic cleavage of the  
358 hemagglutinin polypeptide of influenza virus. Function of the uncleaved polypeptide HA.  
359 *Virology* 52, 199-212.

360 Li, Q., Sun, X., Li, Z., Liu, Y., Vavricka, C.J., Qi, J., Gao, G.F., 2012. Structural and  
361 functional characterization of neuraminidase-like molecule N10 derived from bat influenza  
362 A virus. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18897-18902.

363 Lichty, B.D., Power, A.T., Stojdl, D.F., Bell, J.C., 2004. Vesicular stomatitis virus: re-  
364 inventing the bullet. *Trends Mol. Med.* 10, 210-216.

365 Maeda, K., Hondo, E., Terakawa, J., Kiso, Y., Nakaichi, N., Endoh, D., Sakai, K.,  
366 Morikawa, S., Mizutani, T., 2008. Isolation of novel adenovirus from fruit bat (*Pteropus*  
367 *dasymallus yayeyamae*). *Emerg. Infect. Dis.* 14, 347-349.

368 Makarova, N.V., Ozaki, H., Kida, H., Webster, R.G., Perez, D.R., 2003. Replication and  
369 transmission of influenza viruses in Japanese quail. *Virology* 310, 8-15.

370 Maruyama, J., Miyamoto, H., Kajihara, M., Ogawa, H., Maeda, K., Sakoda, Y., Yoshida,  
371 R., Takada, A., 2014. Characterization of the Envelope Glycoprotein of a Novel Filovirus,  
372 Lloviu Virus. *J. Virol.* 88, 99-109.

373 Matlin, K.S., Reggio, H., Helenius, A., Simons, K., 1981. Infectious entry pathway of  
374 influenza virus in a canine kidney cell line. *J. Cell Biol.* 91, 601-613.

375 Muramatsu, M., Yoshida, R., Miyamoto, H., Tomabechei, D., Kajihara, M., Maruyama, J.,  
376 Kimura, T., Manzoor, R., Ito, K., Takada, A., 2013. Heterosubtypic Antiviral Activity of  
377 Hemagglutinin-Specific Antibodies Induced by Intranasal Immunization with Inactivated  
378 Influenza Viruses in Mice. *PLoS One* 8, e71534.

379 Nakayama, E., Tomabechi, D., Matsuno, K., Kishida, N., Yoshida, R., Feldmann, H.,  
380 Takada, A., 2011. Antibody-dependent enhancement of Marburg virus infection. *J. Infect.*  
381 *Dis.* 204 Suppl 3, S978-985.

382 Narahashi, Y., Shibuya, K., Yanagita, M., 1968. Studies on proteolytic enzymes (pronase)  
383 of *Streptomyces griseus* K-1. II. Separation of exo- and endopeptidases of pronase. *J.*  
384 *Biochem.* 64, 427-437.

385 Niwa, H., Yamamura, K., Miyazaki, J., 1991. Efficient selection for high-expression  
386 transfectants with a novel eukaryotic vector. *Gene* 108, 193-199.

387 Perez, D.R., Lim, W., Seiler, J.P., Yi, G., Peiris, M., Shortridge, K.F., Webster, R.G., 2003.  
388 Role of quail in the interspecies transmission of H9 influenza A viruses: molecular changes  
389 on HA that correspond to adaptation from ducks to chickens. *J. Virol.* 77, 3148-3156.

390 Roche, S., Albertini, A.A., Lepault, J., Bressanelli, S., Gaudin, Y., 2008. Structures of  
391 vesicular stomatitis virus glycoprotein: membrane fusion revisited. *Cell. Mol. Life Sci.* 65,  
392 1716-1728.

393 Rust, M.J., Lakadamyali, M., Zhang, F., Zhuang, X., 2004. Assembly of endocytic  
394 machinery around individual influenza viruses during viral entry. *Nat. Struct. Mol. Biol.*  
395 11, 567-573.

396 Sakai, K., Ami, Y., Tahara, M., Kubota, T., Anraku, M., Abe, M., Nakajima, N., Sekizuka,  
397 T., Shirato, K., Suzaki, Y., Aina, A., Nakatsu, Y., Kanou, K., Nakamura, K., Suzuki, T.,  
398 Komase, K., Nobusawa, E., Maenaka, K., Kuroda, M., Hasegawa, H., Kawaoka, Y.,  
399 Tashiro, M., Takeda, M., 2014. The host protease TMPRSS2 plays a major role in in vivo  
400 replication of emerging H7N9 and seasonal influenza viruses. *J. Virol.* 88, 5608-5616.

401 Scholtissek, C., Burger, H., Kistner, O., Shortridge, K.F., 1985. The nucleoprotein as a  
402 possible major factor in determining host specificity of influenza H3N2 viruses. *Virology*  
403 147, 287-294.

404 Smith, I., Wang, L.F., 2013. Bats and their virome: an important source of emerging  
405 viruses capable of infecting humans. *Curr. Opin. Virol.* 3, 84-91.

406 Su, B., Wurtzer, S., Rameix-Welti, M.A., Dwyer, D., van der Werf, S., Naffakh, N., Clavel,  
407 F., Labrosse, B., 2009. Enhancement of the influenza A hemagglutinin (HA)-mediated cell-  
408 cell fusion and virus entry by the viral neuraminidase (NA). *PLoS One* 4, e8495.

409 Sun, X., Shi, Y., Lu, X., He, J., Gao, F., Yan, J., Qi, J., Gao, G.F., 2013. Bat-derived  
410 influenza hemagglutinin H17 does not bind canonical avian or human receptors and most  
411 likely uses a unique entry mechanism. *Cell Rep.* 3, 769-778.

412 Suzuki, Y., Ito, T., Suzuki, T., Holland, R.E., Jr., Chambers, T.M., Kiso, M., Ishida, H.,  
413 Kawaoka, Y., 2000. Sialic acid species as a determinant of the host range of influenza A  
414 viruses. *J. Virol.* 74, 11825-11831.

415 Takada, A., Robison, C., Goto, H., Sanchez, A., Murti, K.G., Whitt, M.A., Kawaoka, Y.,  
416 1997. A system for functional analysis of Ebola virus glycoprotein. *Proc. Natl. Acad. Sci.*  
417 *U. S. A.* 94, 14764-14769.

418 Tong, S., Li, Y., Rivaller, P., Conrardy, C., Castillo, D.A., Chen, L.M., Recuenco, S.,  
419 Ellison, J.A., Davis, C.T., York, I.A., Turmelle, A.S., Moran, D., Rogers, S., Shi, M., Tao,  
420 Y., Weil, M.R., Tang, K., Rowe, L.A., Sammons, S., Xu, X., Frace, M., Lindblade, K.A.,  
421 Cox, N.J., Anderson, L.J., Rupprecht, C.E., Donis, R.O., 2012. A distinct lineage of  
422 influenza A virus from bats. *Proc. Natl. Acad. Sci. U. S. A.* 109, 4269-4274.

423 Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco,  
424 S., Gomez, J., Chen, L.M., Johnson, A., Tao, Y., Dreyfus, C., Yu, W., McBride, R.,  
425 Carney, P.J., Gilbert, A.T., Chang, J., Guo, Z., Davis, C.T., Paulson, J.C., Stevens, J.,  
426 Rupprecht, C.E., Holmes, E.C., Wilson, I.A., Donis, R.O., 2013. New world bats harbor  
427 diverse influenza A viruses. *PLoS Pathog.* 9, e1003657.

428 Uchida, Y., Tsukada, Y., Sugimori, T., 1977. Distribution of neuraminidase in *Arthrobacter*  
429 and its purification by affinity chromatography. *J. Biochem.* 82, 1425-1433.

430 Uchida, Y., Kanehira, K., Mase, M., Takemae, N., Watanabe, C., Usui, T., Fujimoto, Y.,  
431 Ito, T., Igarashi, M., Ito, K., Takada, A., Sakoda, Y., Okamatsu, M., Yamamoto, Y.,  
432 Nakamura, K., Kida, H., Hiromoto, Y., Tsuda, T., Saito, T., 2011. Genetic characterization  
433 and susceptibility on poultry and mammal of H7N6 subtype avian influenza virus isolated  
434 in Japan in 2009. *Vet. Microbiol.* 147, 1-10.

435 Wang, L.F., Walker, P.J., Poon, L.L., 2011. Mass extinctions, biodiversity and  
436 mitochondrial function: are bats 'special' as reservoirs for emerging viruses? *Curr. Opin.*  
437 *Virology* 1, 649-657.

438 Webster, R.G., Bean, W.J., Gorman, O.T., Chambers, T.M., Kawaoka, Y., 1992. Evolution  
439 and ecology of influenza A viruses. *Microbiol. Rev.* 56, 152-179.

440 Wiley, D.C., Skehel, J.J., 1987. The structure and function of the hemagglutinin membrane  
441 glycoprotein of influenza virus. *Annu. Rev. Biochem.* 56, 365-394.

442 Wilson, I.A., Skehel, J.J., Wiley, D.C., 1981. Structure of the haemagglutinin membrane  
443 glycoprotein of influenza virus at 3 Å resolution. *Nature* 289, 366-373.

444 Wong, S., Lau, S., Woo, P., Yuen, K.Y., 2007. Bats as a continuing source of emerging  
445 infections in humans. *Rev. Med. Virol.* 17, 67-91.

446 Zhou, B., Ma, J., Liu, Q., Bawa, B., Wang, W., Shabman, R.S., Duff, M., Lee, J., Lang, Y.,  
447 Cao, N., Nagy, A., Lin, X., Stockwell, T.B., Richt, J.A., Wentworth, D.E., Ma, W., 2014.  
448 Characterization of uncultivable bat influenza virus using a replicative synthetic virus.  
449 *PLoS Pathog.* 10, e1004420.

450 Zhu, X., Yang, H., Guo, Z., Yu, W., Carney, P.J., Li, Y., Chen, L.M., Paulson, J.C., Donis,  
451 R.O., Tong, S., Stevens, J., Wilson, I.A., 2012. Crystal structures of two subtype N10  
452 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active  
453 site. *Proc. Natl. Acad. Sci. U. S. A.* 109, 18903-18908.

454 Zhu, X., Yu, W., McBride, R., Li, Y., Chen, L.M., Donis, R.O., Tong, S., Paulson, J.C.,  
455 Wilson, I.A., 2013. Hemagglutinin homologue from H17N10 bat influenza virus exhibits  
456 divergent receptor-binding and pH-dependent fusion activities. *Proc. Natl. Acad. Sci. U. S.*  
457 *A.* 110, 1458-1463.



458 **Figure legends**

459 **Fig. 1 Transmission electron microscopy of pseudotyped VSVs.** VSV $\Delta$ G\*-H17N10 (A),  
460 -H18N11 (B), -H3N2 (C) -H17 (D), -H18 (E), -H3 (F), -N10 (G), -N11 (H), -N2 (I) and  
461 VSV $\Delta$ G\*-G (J) were fixed and stained as described in Materials and Methods. For immune  
462 transmission electron microscopy of VSV $\Delta$ G\*-H17N10, anti-HA2 monoclonal antibody  
463 (K) and anti-N10 NA mouse serum (L) were used. Scale bars represent 100 nm.

464 Arrowheads indicate gold particles.

465

466 **Fig. 2 Infectivities of pseudotyped VSVs in several cell lines.** VSV $\Delta$ G\*-WSN, -Aichi, -  
467 H17N10, -H18N11, and VSV $\Delta$ G\*-G were inoculated into several cell lines (Table 1).

468 Infectious units (IUs) of each virus in different cell lines were determined by counting the  
469 number of GFP-expressing cells. Each experiment was performed three times, and averages  
470 and standard deviations are shown. Infectivities of VSV $\Delta$ G\*-H17N10 and -H18N11 in  
471 some cell lines were under the limit of detection ( $\dagger$ ). Significant differences (student's t-  
472 test) were found between MDCK and any of the bat cell lines ( $P < 0.01$ ).

473

474 **Fig. 3 Infectivities of pseudotyped VSVs with BatIV HAs and/or NAs in IndFSPT1**

475 **cells.** (A) VSV $\Delta$ G\*-Aichi, -H17N10, and -H18N11 were treated with or without trypsin  
476 (final concentration 0.0005%) for 30 minutes at 37°C and then mixed with SDS-PAGE

477 sample buffer with 5% 2-mercaptoethanol. After SDS-PAGE, separated proteins were

478 detected by western blotting with anti-H3 chicken antiserum and anti-HA2 monoclonal

479 antibody 3N12-6-4. (B) VSVs pseudotyped with HAs and/or NAs of WSN and Aichi and

480 VSVΔG\*-H17N10, -H17, -N10, -H18N11, -H18, and -N11 were inoculated to IndFSPT1  
481 cells. Infectious units (IUs) were determined by counting the number of GFP-expressing  
482 cells. Each experiment was performed three times, and averages and standard deviations are  
483 shown. Infectivities of VSV pseudotyped with NAs alone were under the limit of detection  
484 (†). Statistical significance was calculated using student's t-test (\*P < 0.01).

485

486 **Fig. 4 Effects of chemical and enzymatic modification on infectivities of pseudotyped**

487 **VSVs.** IndFSPT1 cells were treated with ammonium chloride (A), tunicamycin (B),  
488 pronase (C), or neuraminidase (D) as described in Materials and Methods. Treated cells  
489 were then infected with VSVΔG\*-WSN, -Aichi, -H17N10, -H18N11, and VSVΔG\*-G  
490 appropriately diluted to yield 200–1000 IUs. The percentages of infectivity were  
491 determined by setting the number of the untreated cells to 100%. Each experiment was  
492 performed three times, and averages and standard deviations are shown. Cell viabilities  
493 were measured by the alamar blue assay (E). The percentages of fluorescence were  
494 determined by setting the number of the untreated cells to 100%. Each experiment was  
495 performed three times, and averages and standard deviations are shown. Statistical  
496 significances compared to untreated cells were calculated using student's t-test (\*P < 0.01).

1 **Table 1** Origins of cell lines used in this study

<b>Cell line</b>	<b>Species</b>	<b>Zoological name</b>	<b>Organ</b>
Vero E6	African green monkey	<i>Chlorocebus</i> sp.	Kidney
HEK293	Human	<i>Homo sapiens</i>	Kidney
MDCK	Dog	<i>Canis lupus familiaris</i>	Kidney
SK-L	Pig	<i>Sus scrofa domesticus</i>	Kidney
QT6	Japanese quail	<i>Coturnix japonica</i>	Muscle
BKT1	Greater horseshoe bat <sup>a</sup>	<i>Rhinolophus ferrumequinum</i>	Kidney
FBKT1	Yaeyama flying fox <sup>a</sup>	<i>Pteropus dasymallus yayeyamae</i>	Kidney
YubFKT1	Eastern bent-winged bat <sup>a</sup>	<i>Miniopterus fuliginosus</i>	Kidney
IndFSPT1	Indian flying fox <sup>a</sup>	<i>Pteropus giganteus</i>	Spleen
DemKT1	Leschenault's rousette <sup>a</sup>	<i>Rousettus leschenaultii</i>	Kidney
ZFBK11-97	Gambian epauletted fruit bat <sup>a</sup>	<i>Epomophorus gambianus</i>	Kidney
SuBK12-08	Schreiber's bat <sup>a</sup>	<i>Miniopterus schreibersii</i>	Kidney
ZFBS13-75A	Straw-coloured fruit bat <sup>b</sup>	<i>Eidolon helvum</i>	Spleen

2 <sup>a</sup>Previously described (Maruyama et al., 2014).

3 <sup>b</sup>Determined by habitat and morphology.




Fig. 1 Maruyama et al




Fig. 2 Maruyama et al



**A****B**

Fig. 3 Maruyama et al

